Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Mendelsohn joins Merrimack board

This article was originally published in Scrip

Executive Summary

Merrimack Pharmaceuticals, a biopharmaceutical company developing innovative medicines paired with companion diagnostics to treat cancer, has appointed Dr John Mendelsohn to its board of directors. Dr Mendelsohn served as president of the University of Texas MD Anderson Cancer Center from 1996-2011 and remains on the faculty as co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017860

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel